From the Boston Globe Business Team
Pro-Pharmaceuticals reports "promising" data
October 11, 2007 08:01 AM
Email|
Comments (0)|
Text size
–
+
Pro-Pharmaceuticals Inc. of Newton reported "promising early data" from a Phase II trial of a colorectal cancer treatment.
The trial is for a first-line treatment of patients with metastatic, unresectable colorectal cancer who are unable to tolerate intensive chemotherapy, the company said.
Pro-Pharmaceuticals reported that three of seven evaluable patients in the test have experienced tumor shrinkage of greater than 30 percent; in addition, none of the patients in the test experienced severe side effects.
(By Chris Reidy, Globe staff)
